Clinical-stage HBV Potential partnership or licensing discussions around ATI-2173-based regimens for chronic hepatitis B, targeting collaborations with larger pharma to advance a curative combination therapy.

Financing momentum Leverage recent and past fundraising activity to explore strategic investments, co-development deals, or milestone-driven partnerships that align with Antios Therapeutics’ clinical trajectory and upcoming data milestones.

Early-stage team Given a lean team and clinical focus, offer R&D outsourcing, CRO partnerships, or translational science collaborations to accelerate development while expanding Antios’ execution capabilities.

HBV Insights Position solutions around HBV assays, analytics, biomarker strategy, and regulatory science to support ATI-2173 trials, potentially monetizing advisory or platform capabilities.

Clinical visibility Capitalize on past conference exposure and ongoing phase-related milestones to secure speaking slots, sponsored studies, or strategic investor relations activities that raise profile and attract partners.